Abstract
Acute respiratory distress syndrome (ARDS) remains without effective targeted reparative therapies and continues to carry a high mortality rate. Here, we comment on a recent study by Zhang et al, who identify a CD146+ subpopulation of mesenchymal stromal cells (MSCs) with superior reparative function in lipopolysaccharide-induced ARDS in mice. Compared with CD146- MSCs, CD146+ MSCs secreted higher levels of reparative paracrine mediators, including hepatocyte growth factor, vascular endothelial growth factor, prostaglandin E2 (PGE2), and angiopoietin 1, better preserved endothelial junctional proteins (VE-cadherin, zonula occludens-1), and more effectively modulated T cell and macrophage phenotypes. Mechanistic studies link these effects to a nuclear factor kappa B (NF-κB)/cyclooxygenase-2/PGE2 signaling axis, as pharmacologic blockade of NF-κB (caffeic acid phenethyl ester) abrogated the benefits. We place these results in the context of MSC heterogeneity research, highlight strengths (mechanistic depth, in vivo validation) and limitations (single animal model, reliance on cell lines rather than primary human cells), and propose next steps: Testing efficacy across diverse ARDS etiologies (viral, aspiration), validating effects in primary human alveolar and endothelial cells, delineating the CD146/NF-κB cascade, developing potency biomarkers (e.g., PGE2), and performing rigorous safety profiling. Strategies to enrich or prime MSCs for CD146-associated NF-κB/cyclooxygenase-2/PGE2 program activity may provide a practical route to higher potency.